News & Media

Boehringer Ingelheim News, Press Releases & Information

Quick access to the latest company news, including corporate, research & development and human pharmaceuticals for members of the media.

Press Release Subscription

Please submit the form below to receive press releases via email.

Information for

- Press Release
PRESS RELEASE 31 May 2018 at 09:00

Real-world analysis reinforces that Gilotrif^{^®} dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

Read moreon
Real-world analysis reinforces that Gilotrif^{^®} dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy
PRESS RELEASE 21 May 2018 at 14:00

Efficacy and safety of Ofev^{^®} (nintedanib) reinforced in new presentations at ATS 2018

Read moreon
Efficacy and safety of Ofev^{^®} (nintedanib) reinforced in new presentations at ATS 2018
PRESS RELEASE 04 May 2018 at 08:00

Praxbind^{^®}, Specific Reversal Agent for Pradaxa^{^®}, Now Available in 3,200 Hospitals Nationwide

Read moreon
Praxbind^{^®}, Specific Reversal Agent for Pradaxa^{^®}, Now Available in 3,200 Hospitals Nationwide
PRESS RELEASE 25 Apr 2018 at 08:30

Boehringer Ingelheim R&D pushes to transcend disease boundaries

Read moreon Boehringer Ingelheim R&D pushes to transcend disease boundaries
- Press Release
PRESS RELEASE 25 Apr 2018 at 04:30

Boehringer Ingelheim has a very successful 2017 financial year

Read moreon Boehringer Ingelheim has a very successful 2017 financial year
PRESS RELEASE 19 Apr 2018 at 09:00

Boehringer Ingelheim and HealthPrize Expand Successful Digital Patient Support Program

Read moreon Boehringer Ingelheim and HealthPrize Expand Successful Digital Patient Support Program
PRESS RELEASE 17 Apr 2018 at 08:00

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

Read moreon FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa
PRESS RELEASE 16 Apr 2018 at 08:00

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

Read moreon Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease
- Press Release
PRESS RELEASE 04 Apr 2018 at 12:00

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Read moreon Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
PRESS RELEASE 29 Mar 2018 at 08:00

New Large-Scale Trial Results Show Stiolto^{^®} Respimat^{^®} Prevents COPD Exacerbations Better Than Spiriva^{^®} Respimat^{^®}

Read moreon
New Large-Scale Trial Results Show Stiolto^{^®} Respimat^{^®} Prevents COPD Exacerbations Better Than Spiriva^{^®} Respimat^{^®}
PRESS RELEASE 28 Mar 2018 at 08:00

Boehringer Ingelheim and Minor League Baseball Team Up to Raise Awareness of Rare Lung Disease - IPF

Read moreon Boehringer Ingelheim and Minor League Baseball Team Up to Raise Awareness of Rare Lung Disease - IPF
PRESS RELEASE 19 Mar 2018 at 08:00

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Read moreon FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
- Press Release
PRESS RELEASE 13 Mar 2018 at 09:00

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

Read moreon Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
PRESS RELEASE 09 Mar 2018 at 08:00

Boehringer Ingelheim to Present New Research on Pradaxa and Specific Reversal Agent Praxbind at American College of Cardiology Scientific Session

Read moreon Boehringer Ingelheim to Present New Research on Pradaxa and Specific Reversal Agent Praxbind at American College of Cardiology Scientific Session
PRESS RELEASE 06 Mar 2018 at 08:00

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance^{^®} with new exercise capacity trials

Read moreon
Boehringer Ingelheim and Lilly expand heart failure program for Jardiance^{^®} with new exercise capacity trials
PRESS RELEASE 16 Feb 2018 at 08:00

New initiative raises awareness of scleroderma through real-life stories of those living with the rare disease

Read moreon New initiative raises awareness of scleroderma through real-life stories of those living with the rare disease
- Press Release
PRESS RELEASE 09 Feb 2018 at 06:05

Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials

Read moreon Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials
PRESS RELEASE 31 Jan 2018 at 09:15

Boehringer Ingelheim Announces Paul Fonteyne to Retire at the end of 2018. Wolfgang Baiker Appointed U.S. President & CEO Effective March 1, 2018.

Read moreon Boehringer Ingelheim Announces Paul Fonteyne to Retire at the end of 2018. Wolfgang Baiker Appointed U.S. President & CEO Effective March 1, 2018.
PRESS RELEASE 25 Jan 2018 at 10:12

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa^{^®} Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

Read moreon
New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa^{^®} Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment
PRESS RELEASE 16 Jan 2018 at 09:00

FDA approves new indication for Gilotrif^{^®} in EGFR mutation-positive NSCLC

Read moreon
FDA approves new indication for Gilotrif^{^®} in EGFR mutation-positive NSCLC

Search form

News & Media

Boehringer Ingelheim News, Press Releases & Information

Press Release Subscription